BR112020022443A2 - epitopos de células t auxiliares promíscuos artificiais que facilitam a produção de anticorpos alvejados com resposta inflamatória de células t limitada - Google Patents

epitopos de células t auxiliares promíscuos artificiais que facilitam a produção de anticorpos alvejados com resposta inflamatória de células t limitada Download PDF

Info

Publication number
BR112020022443A2
BR112020022443A2 BR112020022443-0A BR112020022443A BR112020022443A2 BR 112020022443 A2 BR112020022443 A2 BR 112020022443A2 BR 112020022443 A BR112020022443 A BR 112020022443A BR 112020022443 A2 BR112020022443 A2 BR 112020022443A2
Authority
BR
Brazil
Prior art keywords
fact
epitope
peptide
helper
antigenic site
Prior art date
Application number
BR112020022443-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Chang Yi Wang
Original Assignee
Ubi Ip Holdings
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ubi Ip Holdings filed Critical Ubi Ip Holdings
Publication of BR112020022443A2 publication Critical patent/BR112020022443A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112020022443-0A 2018-05-04 2019-05-03 epitopos de células t auxiliares promíscuos artificiais que facilitam a produção de anticorpos alvejados com resposta inflamatória de células t limitada BR112020022443A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862667123P 2018-05-04 2018-05-04
US62/667,123 2018-05-04
PCT/US2019/030649 WO2019213555A1 (en) 2018-05-04 2019-05-03 Artificial promiscuous t helper cell epitopes that facilitate targeted antibody production with limited t cell inflammatory response

Publications (1)

Publication Number Publication Date
BR112020022443A2 true BR112020022443A2 (pt) 2021-02-09

Family

ID=68386088

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020022443-0A BR112020022443A2 (pt) 2018-05-04 2019-05-03 epitopos de células t auxiliares promíscuos artificiais que facilitam a produção de anticorpos alvejados com resposta inflamatória de células t limitada

Country Status (12)

Country Link
US (2) US20220023400A1 (enExample)
EP (1) EP3790581A4 (enExample)
JP (2) JP2021523127A (enExample)
KR (1) KR20210010873A (enExample)
CN (1) CN112218655A (enExample)
AU (1) AU2019262609A1 (enExample)
BR (1) BR112020022443A2 (enExample)
CA (1) CA3099296A1 (enExample)
MX (1) MX2020011733A (enExample)
SG (1) SG11202010942WA (enExample)
TW (1) TWI754817B (enExample)
WO (1) WO2019213555A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12543381B2 (en) * 2019-05-31 2026-02-03 Semiconductor Energy Laboratory Co., Ltd. Method for manufacturing semiconductor device
CN112876570B (zh) * 2021-02-09 2022-07-26 中国农业科学院生物技术研究所 非洲猪瘟病毒疫苗及其制备方法
CA3261968A1 (en) * 2022-07-14 2024-01-18 Vaxxinity, Inc. IMMUNOGENEOUS TAU PEPTIDE CONSTRUCTIONS
CN118812726B (zh) * 2024-06-26 2025-05-16 西北民族大学 脑心肌炎多抗原表位重组蛋白及其在制备脑心肌炎疫苗中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025468A (en) * 1998-06-20 2000-02-15 United Biomedical, Inc. Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides
TWI229679B (en) * 1998-06-20 2005-03-21 United Biomedical Inc Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens
US20140088020A1 (en) * 1999-08-30 2014-03-27 David S Terman Composition and Methods for Treatment of Cancer
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
DE60336848D1 (de) * 2002-09-12 2011-06-01 Univ California Immunogene und entsprechende antikörper, die spezifisch sind für häufige hochmolekulare aggregations-zwischenprodukte von amyloiden aus proteinen unterschiedlicher sequenz
JP5863582B2 (ja) * 2012-07-02 2016-02-16 東京エレクトロン株式会社 プラズマ処理装置、及び温度制御方法
CN105992587A (zh) * 2013-02-18 2016-10-05 春堤制药公司 作为疫苗佐剂和治疗试剂的短寡核苷酸的设计
US9102752B2 (en) * 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
US10450352B2 (en) * 2016-03-23 2019-10-22 Board Of Regents, The University Of Texas System Engineered polypeptides for antigen delivery

Also Published As

Publication number Publication date
SG11202010942WA (en) 2020-12-30
JP2021523127A (ja) 2021-09-02
EP3790581A1 (en) 2021-03-17
EP3790581A4 (en) 2022-06-22
US20220023400A1 (en) 2022-01-27
WO2019213555A1 (en) 2019-11-07
MX2020011733A (es) 2021-01-15
CA3099296A1 (en) 2019-11-07
TWI754817B (zh) 2022-02-11
JP2024095743A (ja) 2024-07-10
AU2019262609A1 (en) 2020-12-03
KR20210010873A (ko) 2021-01-28
TW201946649A (zh) 2019-12-16
CN112218655A (zh) 2021-01-12
US20250262286A1 (en) 2025-08-21

Similar Documents

Publication Publication Date Title
JP7555598B2 (ja) 合成ペプチド免疫原のための免疫刺激薬としての人工無差別ｔヘルパー細胞エピトープ
US20250262286A1 (en) Artificial promiscuous t helper cell epitopes that facilitate targeted antibody production with limited t cell inflammatory response
AU764961B2 (en) Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides
JPH06510051A (ja) Ｈｌａ−制限型ｂ型肝炎ウィルスのｃｔｌエピトープ
JP2010536878A (ja) インフルエンザタンパク質を製造および使用する組成物および方法
TWI769424B (zh) 針對降鈣素基因相關胜肽（ｃｇｒｐ）的胜肽免疫原及其用於預防和治療偏頭痛的製劑
CN113227116A (zh) 针对源自c9orf72二肽重复蛋白的肽免疫原构建体
JP5901084B2 (ja) ペプチドアジュバント
TWI823051B (zh) 針對垂體腺苷酸環化酶激活胜肽的胜肽免疫原及其預防和治療偏頭痛的製劑
TW202142551A (zh) 針對pcsk9胜肽免疫原及其預防和治療pcsk9介導疾病的製劑
HK40045220A (en) Artificial promiscuous t helper cell epitopes that facilitate targeted antibody production with limited t cell inflammatory response
RU2839585C2 (ru) Искусственные неизбирательные эпитопы клеток т-хелперов как иммунные стимуляторы для синтетических пептидных иммуногенов
WO2024015611A2 (en) Tau peptide immunogen constructs
WO2014074509A1 (en) Production of an immunogen using a plant virus
Ben-Yedidia A peptide-based vaccine against influenza
Levi A synthetic approach to influenza vaccines

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements